Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Shionogi Licenses Cognitive Disorders Treatment Candidate from Tetra
December 20, 2018
- Shonan iPark Sets Up Consortium for Commercializing Disease Prevention
December 20, 2018
- Otezla Reduces Oral Ulcers in Japanese Behcet’s Disease Patients in PIII Study: Celgene
December 20, 2018
- Takeda Likely to Make NYSE Debut on Christmas Eve
December 19, 2018
- Bristol-Myers, Eisai Unit Ink I/O Collaboration
December 19, 2018
- Daiichi Sankyo Grants ROS1/NTRK Inhibitor Rights to AnHeart
December 19, 2018
- Shionogi Earns CHMP OK for Naldemedine
December 19, 2018
- Novo Links with H2 Inc. for Diabetes Treatment App
December 19, 2018
- Takeda, Alphabet's Health Unit Team Up on Japanese Parkinson’s Patient Research
December 19, 2018
- Adcetris Label Expansion Gets European Panel Nod: Takeda
December 18, 2018
- Hisamitsu Files Asenapine Transdermal Patch for Schizophrenia in US
December 18, 2018
- Eisai Grants to Eurofarma Exclusive Rights for Obesity Agent Lorcaserin in Brazil
December 18, 2018
- Efficacy of Fentos Tape for Cancer Pain in Opioid-Naïve Patients Confirmed in PIII Study: Hisamitsu
December 17, 2018
- Janssen Applies for Darzalex for Previously Untreated Multiple Myeloma Patients
December 17, 2018
- Gilead Files HIV Triplet Biktarvy in Japan, JT Pact Termination Set for Jan. 1
December 17, 2018
- Astellas Makes Full Inroads into I/O Arena with Potenza Buyout
December 17, 2018
- Lundbeck Japan to Quadruple Workforce by Next Summer, Eyes Vortioxetine Launch: Chief
December 14, 2018
- Astellas CEO Sees Cell Therapy Biz Model Established by “around 2030”
December 14, 2018
- ASKA to Review 5-Year Biz Plan after Hit by NHI Price Cut, Despite New Drug Launches
December 14, 2018
- Daiichi Sankyo Mulling Moving Up DS-8201 Filing to FY2019: Oncology Chief
December 13, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…